Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

147.73USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$147.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,028,838
52-wk High
$148.44
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

J&J Vision Says Singapore National Eye Centre, Singapore Eye Research Institute And Co Enter Research Collaboration
Monday, 12 Nov 2018 

Nov 12 (Reuters) - :J&J VISION - SINGAPORE NATIONAL EYE CENTRE, SINGAPORE EYE RESEARCH INSTITUTE AND CO SET SIGHTS ON HALTING GLOBAL MYOPIA EPIDEMIC.J&J VISION- NEW $26.35 MILLION COLLABORATION SEEKS PREVENTION AND TREATMENT SOLUTIONS TO ADDRESS RISING BURDEN OF CONDITION.  Full Article

Johnson & Johnson Announces Offer To Buy CiZ Holdings Co Ltd
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - J&J ::JOHNSON & JOHNSON ANNOUNCES OFFER TO ACQUIRE CI:Z HOLDINGS CO., LTD..ACQUISITION WILL INCLUDE COMPANY'S RANGE OF BRANDS COMPRISING DR.CI:LABO, LABO LABO AND GENOMER LINE OF SKINCARE PRODUCTS..EXPECTS TO LAUNCH TENDER OFFER ON OCTOBER 29, 2018..TENDER OFFER IS EXPECTED TO CLOSE IN Q1 OF 2019.UPON COMPLETION OF TENDER OFFER, INTENDS TO CONDUCT SQUEEZE-OUT PROCEDURE TO BUY REMAINING SHARES IN COMPANY THAT WERE NOT TENDERED IN TENDER OFFER.JOHNSON & JOHNSON TENDER OFFER IS FOR 5900 YEN PER SHARE OF CI:Z HOLDINGS CO, WHICH IS EQUAL TO ABOUT 230 BILLION YEN.  Full Article

J&J Sets Quarterly Cash Dividend Of $0.90 Per Share
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Johnson & Johnson ::SETS QUARTERLY CASH DIVIDEND OF $0.90PER SHARE.  Full Article

Health Canada Has Approved Invokana
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Johnson & Johnson ::HEALTH CANADA HAS APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), THE FIRST SGLT2 INHIBITOR IN CANADA TO RECEIVE THIS INDICATION(1).JANSSEN PHARMACEUTICAL SAYS HEALTH CANADA APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS.  Full Article

Genmab Q3 Net Sales of Darzalex (Daratumumab) at $498 Mln
Tuesday, 16 Oct 2018 

Oct 16 (Reuters) - Genmab ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2018.NET SALES OF DARZALEX IN Q3 OF 2018 TOTALED USD 498 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..GROWTH WAS PARTIALLY OFFSET BY A ONE-TIME ADJUSTMENT OUTSIDE U.S. RELATED TO ACCRUALS FOR RETROACTIVE PRICING ADJUSTMENTS.ADJUSTMENTS NEGATIVELY IMPACTED THIS WORLDWIDE OPERATIONAL GROWTH BY 16 PERCENTAGE POINTS..2018 Q3 NET SALES WERE USD 318 MILLION IN U.S. AND USD 180 MILLION IN REST OF WORLD..  Full Article

Prime Therapeutics Inks Value-Based Contract For Stelara® With Janssen
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Prime Therapeutics::PRIME THERAPEUTICS INKS VALUE-BASED CONTRACT FOR STELARA® WITH JANSSEN.PRIME THERAPEUTICS - MEDICAL & PHARMACY CLAIMS DATA WILL TRACK HOW LONG PATIENTS STAY ON STELARA, INFORMING CO'S CLINICAL PROGRAMS.  Full Article

Geron Announces Discontinuation Of Imetelstat Collaboration By Janssen
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Geron Corp ::GERON ANNOUNCES DISCONTINUATION OF IMETELSTAT COLLABORATION BY JANSSEN.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - REGAINS GLOBAL RIGHTS TO IMETELSTAT PROGRAM.GERON CORP - EFFECTIVE DATE OF TERMINATION IS SEPTEMBER 28, 2018.GERON - TRANSITION OF IMETELSTAT PROGRAM TO GERON IS EXPECTED TO OCCUR OVER APPROXIMATELY 12 MONTHS WITH OPERATIONAL SUPPORT FROM JANSSEN.GERON - JANSSEN IS EXPECTED TO SUPPLY IMETELSTAT TO GERON FOR UP TO 24 MONTHS DURING TRANSITION PERIOD FOR CLINICAL MANUFACTURING.GERON CORP - REVISED ITS FINANCIAL PROJECTIONS AND NOW ANTICIPATES 2018 OPERATING EXPENSES TO BE APPROXIMATELY $37 MILLION.GERON CORP - PLANS TO INITIATE PHASE 3 PORTION OF IMERGE AFTER SPONSORSHIP OF ONGOING IMETELSTAT CLINICAL TRIALS TRANSFERRED FROM JANSSEN TO CO.GERON CORP - ANTICIPATES PATIENT SCREENING AND ENROLLMENT FOR PHASE 3 PORTION OF IMERGE TO BEGIN BY MID-YEAR OF 2019.GERON CORP - HAS ENGAGED A GLOBAL CONTRACT RESEARCH ORGANIZATION (CRO) TO SUPPORT IMETELSTAT CLINICAL DEVELOPMENT.GERON-AS OF AUG 31, HAD ABOUT $183 MILLION IN CASH, MARKETABLE SECURITIES; EXPECTED TO BE SUFFICIENT TO SUPPORT PLANS TO INITIATE PHASE 3 OF IMERGE IN 2019.GERON - EXPECTS FINAL DATA FROM PHASE 2 PORTION OF IMERGE TO BE AVAILABLE IN 2019.  Full Article

Janssen Pharmaceutical Says Tremfya Improves Long-Term Patient-Reported Outcomes for Plaque Psoriasis
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Johnson & Johnson ::JANSSEN PHARMACEUTICAL SAYS TREMFYA IMPROVES LONG-TERM PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.JANSSEN SAYS DATA SHOW IMPROVEMENTS IN LONG-TERM OUTCOMES IN PATIENTS SWITCHED TO GUSELKUMAB AFTER INADEQUATE RESPONSE TO TREATMENT WITH ADALIMUMAB.  Full Article

Abbvie Announces Imbruvica Plus Rituximab Approval By U.S. FDA For A Rare Type Of Blood Cancer
Monday, 27 Aug 2018 

Aug 27 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB APPROVAL BY U.S. FDA AS FIRST CHEMOTHERAPY-FREE COMBINATION TREATMENT IN ADULTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA, A RARE TYPE OF BLOOD CANCER.ABBVIE INC - IMBRUVICA NOW HAS A TOTAL OF NINE FDA APPROVALS ACROSS SIX DIFFERENT DISEASES.ABBVIE INC - FDA APPROVED IMBRUVICA (IBRUTINIB) PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH A TYPE OF NON-HODGKIN'S LYMPHOMA.  Full Article

Johnson & Johnson Announces Chris Delorefice As Vice President Of Investor Relations
Wednesday, 8 Aug 2018 

Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES CHRIS DELOREFICE AS VICE PRESIDENT OF INVESTOR RELATIONS.J&J - APPOINTMENT OF CHRIS DELOREFICE TO VICE PRESIDENT OF INVESTOR RELATIONS FOR JOHNSON & JOHNSON, EFFECTIVE AUGUST 13, 2018.  Full Article

Photo

Big pharma leaves big gaps: drugmakers urged to do more for poor

LONDON Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday.